SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Summary

Swedish Orphan Biovitrum (SOBI) operates as a bio-pharmaceutical and bio-technology company. The Company develops therapies and drugs for the treatment of haemophilia, inflammation, and genetic diseases. SOBI serves clients worldwide.

Deals Overview

Total Deals4

Valued Deals4

Total Value£ 8.31 B

Avg. Deal Size£ 2.08 B

Market Context

Senior Management

Guido Oelkers
President and CEO
Henrik Karl Stenqvist
CFO
Hakan Bjorklund
Chairman

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy